Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa

ABSTRACT: Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa

PROVIDER: PRJEB85283 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR14219002_1.fastq.gz	Fastqsanger.gz
	ERR14219002_2.fastq.gz	Fastqsanger.gz
	ERR14219102_1.fastq.gz	Fastqsanger.gz
	ERR14219102_2.fastq.gz	Fastqsanger.gz
	ERR14219003_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 286

Similar Datasets

Whole-Genome Sequencing of Ceftazidime-Avibactam resistant KPC-producing Klebsiella pneumoniae strains

Project description:Emergence of Ceftazidime-Avibactam resistant KPC-producing K. pneumoniae (KPC-Kp) during ceftazidime-avibactam-based antimicrobial treatment.

| PRJEB21871 | ENA

Susceptibility to ceftazidime/avibactam in German MDR/XDR Pseudomonas aeruginosa

Project description:Susceptibility to ceftazidime/avibactam in German MDR/XDR Pseudomonas aeruginosa

| PRJEB30639 | ENA

Multi-omics, multi assay analysis of evolved resistance to ceftazidime-avibactam in Pseudomonas aeruginosa, compared to meropenem resistance and co-resistance evolution

Project description:Pseudomonas aeruginosa is a major cause of infection in hospitalised patients, with a large genome which makes it highly versatile and resistant to most antimicrobial agents. Ceftazidime-avibactam (CZA) offers an alternative treatment, but resistance is quickly evolving. There is limited knowledge on the exact resistance mechanisms to this drug, or on cross-resistance to meropenem (MEM). This laboratory experiment aimed to decipher these mechanisms in order to provide guidance for the best treatment choice in meropenem pre-treated P. aeruginosa infections. Six clinical isolates of P. aeruginosa were subjected to multistep resistance selection in sub inhibitory concentrations of CZA and MEM. MICs were also determined in the presence of the efflux pump inhibitor phenyl-Arginine-β-Naphthylamide (PAβN). Molecular analyses were performed by whole genome sequencing, whole -gene- and -protein expression profiles. CRISPR/Cas9 genome editing was performed using a two-plasmid method for selected mutations

2025-05-21 | PXD044998 | Pride

Novel Mechanisms of Antibiotic Resistance in Mismatch Repair-Deficient Pseudomonas aeruginosa hypermutators

Project description:Using in vitro directed evolution, we show that mismatch repair-deficient Pseudomonas aeruginosa can engage novel resistance mechanisms to ceftazidime-avibactam.

2021-08-30 | GSE180086 | GEO

Ceftazidime-Avibactam plus Aztreonam Cocktail for the Treatment of VIM-Producing Pseudomonas aeruginosa Infections.

Project description:Ceftazidime-Avibactam plus Aztreonam for the Treatment of VIM-Producing Pseudomonas aeruginosa Infections.

| PRJEB81449 | ENA

KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae.

Project description:Carbapenem-resistant Enterobacterales, such as Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, represent a major threat to public health due to their rapid spread. Novel drug combinations such as ceftazidime-avibactam (CZA), combining a broad-spectrum cephalosporin along with a broad-spectrum β-lactamase inhibitor, have recently been introduced and have been shown to exhibit excellent activity toward multidrug-resistant KPC-producing Enterobacterales strains. However, CZA-resistant K. pneumoniae isolates are now being increasingly reported, mostly corresponding to producers of KPC variants. In this study, we evaluated in vitro the nature of the mutations in the KPC-2 and KPC-3 β-lactamase sequences (the most frequent KPC-type enzymes) that lead to CZA resistance and the subsequent effects of these mutations on susceptibility to other β-lactam antibiotics. Single-step in vitro selection assays were conducted, resulting in the identification of a series of mutations in the KPC sequence which conferred the ability of those mutated enzymes to confer resistance to CZA. Hence, 16 KPC-2 variants and 10 KPC-3 variants were obtained. Production of the KPC variants in an Escherichia coli recombinant strain resulted in a concomitant increased susceptibility to broad-spectrum cephalosporins and carbapenems, with the exceptions of ceftazidime and piperacillin-tazobactam, compared to wild-type KPC enzymes. Enzymatic assays showed that all of the KPC variants identified exhibited an increased affinity toward ceftazidime and a slightly decreased sensitivity to avibactam, sustaining their impact on CZA resistance. However, their respective carbapenemase activities were concurrently negatively impacted.

| S-EPMC8370223 | biostudies-literature

Transcriptomics analysis during the transient ceftazidime tolerance of Burkholderia pseudomallei

Project description:B. pseudomallei strain K96243 is sensitive to the drug ceftazidime (CAZ), but has been shown to exhibit transient CAZ tolerance when in a biofilm form. To investigate an observed shift in gene expression profile during ceftazidime (CAZ) tolerance and to better understand the mechanistic aspects of this transient tolerance, RNA-sequencing was performed on B. pseudomallei K96243 from the following three growth states: planktonic-free, biofilm, and planktonic shedding cells. Results indicated that the expression of 651 genes (10.97%) were significantly changed in both biofilm (resistant) and planktonic shedding (sensitive) cells in comparison to the planktonic state. Burkholderia biofilm shifts its transcriptome in response to ceftazidime exposure by regulating iron-sulfur stabilizing and metabolic-related genes.

2021-06-30 | GSE168275 | GEO

Laboratory-selected mutants of Enterobacteriaceae with resistance or diminished susceptibility to ceftazidime/avibactam

Project description:Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC- producing Enterobacteriaceae

| PRJEB27344 | ENA

Synergy between mecillinam and ceftazidime/avibactam or avibactam against multi-drug resistant carbapenemase-producing Escherichia coli and Klebsiella pneumoniae.

Project description:Mecillinam/avibactam synergy

| PRJEB50806 | ENA

Mutational Basis of Ceftazidime-Borrelidin A Collateral Sensitivity in Escherichia coli

Project description:Genomics of Collateral Sensitivity

| PRJEB94349 | ENA